Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Assessment of urothelial cancer screening outcomes among patients with Lynch syndrome at rural multidisciplinary clinic.

Alexandra Yudiski, Heather Rocha, Matthew Dzeda et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22618

e22618 Background: The National Comprehensive Cancer Network (NCCN) indicates an increased risk for urinary tract and bladder malignancies in Lynch Syndro...

Membrane-specific HER2 expression by artificial intelligence-based quantitative scoring for prediction of efficacy of trastuzumab deruxtecan in biliary tract cancer (HERB trial): Exploratory analysis of a multicenter, single arm, phase II trial.

Mitsuho Imai, Chigusa Morizane, Woochan Hwang et al. Jun 01, 2025 pp. 4097-4097 10.1200/jco.2025.43.16_suppl.4097

4097 Background: Trastuzumab deruxtecan (T-DXd) showed promising results in patients with HER2-positive biliary tract canc...

The intricacies of illiteracy, an indigenous language, and religious beliefs on oncology and palliative care: Perspectives from Paraguayan healthcare providers.

Maria Agustina Callizo Bedoya, Andrea Magali Del Valle Ochelli, Romina Veron de Astrada Aguilar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24067

e24067 Background: Paraguay is a country with two official languages, Spanish and Guarani. 34.7% of the population speaks both, while 33.4% of the populat...

Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: Results from the TUXEDO-3 phase II trial.

Matthias Preusser, Javier Garde, María Gion et al. Jun 01, 2025 pp. 2005-2005 10.1200/jco.2025.43.16_suppl.2005

2005 Background: BM and LMD are common and severe complications of solid cancers with high morbidity, poor prognosis, and limited treatment options. Antib...

Evidence of a role for oropharyngeal cancer cells with low HPV gene expression in treatment failure.

Devraj Basu, Malay Kumar Sannigrahi, Lovely Raghav et al. Jun 01, 2025 pp. 6058-6058 10.1200/jco.2025.43.16_suppl.6058

6058 Background: A subset of tumor cells with reduced HPV gene expression, here termed HPV-lo cells, are proposed contribute to t...

Real-world effectiveness of first-line chemo-immunotherapy and chemotherapy on ES-SCLC: A propensity score-matched study.

Xiaolin Li, Dan Xiao Li, Hui Jin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20110

e20110 Background: This study aims to evaluate whether the combination of chemotherapy and immunotherapy offers superior efficacy and prognosis compared t...

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: A network meta-analysis.

Ahmed Ibrahim, Laila Shalabi, Ahmed Farid Gadelmawla et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16079

e16079 Background: Integrating immune checkpoint inhibitors (ICIs) with conventional chemotherapy has significantly transformed oncology, creating new tre...

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis.

Stephen J. Freedland, Ugo De Giorgi, Ronald F. Tutrone et al. Jun 01, 2025 pp. 5103-5103 10.1200/jco.2025.43.16_suppl.5103

5103 Background: The phase 3 EMBARK trial demonstrated clinically meaningful improvement in metastasis-free survival and secondary efficacy endpoints with...

Trend analysis of risk factors for early-onset primary colorectal cancer: A population-based time trend analysis using the SEER database.

Bushra Al-Shaikh, Mohammed S. Beshr, Mohamed E. Ali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15717

e15717 Background: Colorectal cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths. The incidence...

Socioeconomic disparities in cardio-oncology breast cancer patients from a single institution.

Sruthi Dontu, Shawn Michael Doss, Stacy Bedore et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e24018

e24018 Background: Breast cancer is associated with significant cardiotoxicity, and underserved populations experience disproportionately higher rates of...

Improving adherence to CDK4/6 inhibitors in breast cancer through remote therapeutic monitoring with real-time adherence tracking and actionable alerts.

Jane Lowe Meisel, Tamar Sapir, Ilana Graetz et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12520

e12520 Background: Oral CDK 4/6 inhibitors (CDK4/6is) have transformed the management of HR+/HER2- breast cancer (BC), offering patients (pts) greater fle...

Mortality trends due to endometrial cancer in the United States: A retrospective analysis from 1999-2020.

Eeshal Fatima, Mahnoor Asghar Keen, Wajeeh Hassan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17628

e17628 Background: Endometrial cancer (EC) is the most common gynecological cancer in the United States (US). The lifetime risk of being diagnosed with EC...

Impact of cancer related fatigue on quality of life of 1,262 patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide phase III RCT.

Jeremy McGuire, Nikesha Gilmore, Joseph John Guido et al. Jun 01, 2025 pp. 12130-12130 10.1200/jco.2025.43.16_suppl.12130

12130 Background: Cancer-related fatigue (CRF) is one of the most common and debilitating symptoms reported by cancer patients, significantly impairing qu...

Lung cancer mortality in Brazil from 2004 to 2023.

Inaiê Maiala De Almeida Miranda, Julia Ernandes Cardoso, João Victor Caparroz Assef et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22578

e22578 Background: Lung cancer is one of the leading causes of death by cancer worldwide. An important risk factor is tobacco smoking. However, cases amon...

Effect of genetically engineered <i>Salmonella typhimurium</i> secreting conantokin G on PD-L1 antibody therapy and tumor regression in colorectal cancer.

Hyo Jin Lee, Solbi Kim, Eunji Kim et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14566

e14566 Background: Engineered attenuated Salmonella represents an intensive strategy for targeting tumors, which enhances the effe...

CD-19 CAR-T cell therapy in adult B-cell ALL patients: A systematic review of clinical trials.

Amara Sofia, Wajeeha Aiman, Muhammad Ashar Ali et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19012

e19012 Background: Chimeric antigen receptor T cell (CAR-T) therapy targeting CD19 has emerged as a transformative modalit...

Prognostic significance of complete blood cell count-derived inflammatory biomarkers in patients with small cell carcinoma of the cervix.

Mingxuan Zhu, Qin Xu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17521

e17521 Background: Inflammatory markers derived from complete blood cell count have previously been considered prognostic indicators for various diseases,...

CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting.

Soo J. Park, Guilherme Rabinowits, Timothy J. Panella et al. Jun 01, 2025 pp. 9533-9533 10.1200/jco.2025.43.16_suppl.9533

9533 Background: Cemiplimab is the first PD-L1 inhibitor approved for the treatment of patients with locally advanced (la) or metastatic (m) cutaneous squ...

Outcomes of elderly patients with early-stage triple-negative breast cancer treated with the KEYNOTE-522 regimen.

Renata Colombo Bonadio, Flavia Balint, Isadora Martins de Sousa et al. Jun 01, 2025 pp. 609-609 10.1200/jco.2025.43.16_suppl.609

609 Background: The KEYNOTE-522 regimen (neoadjuvant pembrolizumab combined with a four-drug chemotherapy backbone, followed by adjuvant pembrolizumab) is...

Protective effects of gallic acid against cadmium-induced neuroinflammation in glioblastoma cells.

Suttinee Phuagkhaopong, Jidapha Sukwattanasombat, Piyanuch Wonganan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14018

e14018 Background: Environmental exposure to cadmium (Cd), a toxic heavy metal, was associated with an increased incidence risk of glioblastoma multiforme...

Analysis of genetic mutation profile and CNS pharmacokinetics in relapsed/refractory primary CNS lymphoma patients responding to novel emavusertib (IRAK4i) and BTKi combination.

Christian Grommes, Anna P. Dabrowska-Iwanicka, Han W. Tun et al. Jun 01, 2025 pp. 2085-2085 10.1200/jco.2025.43.16_suppl.2085

2085 Background: Primary Central Nervous System Lymphoma (PCNSL) is a rare and aggressive non-Hodgkin lymphoma with no approved treatments for relapsed/re...

Clinical significance of the CGRP pathway gene expression in advanced solid tumors: A sub-analysis of MONSTAR-SCREEN-2.

Takao Fujisawa, Naoya Sakamoto, Yoshiaki Nakamura et al. Jun 01, 2025 pp. 2629-2629 10.1200/jco.2025.43.16_suppl.2629

2629 Background: Calcitonin gene-related peptide (CGRP), a neuropeptide associated with pain perception, has emerged as a therapeutic target for migraine....

Drivers of homologous recombination deficiency (HRD) in metastatic colorectal cancer (mCRC).

Paula Romero Lozano, Javier Ros Montañá, Eduardo García-Galea et al. Jun 01, 2025 pp. 3577-3577 10.1200/jco.2025.43.16_suppl.3577

3577 Background: HRD is linked to sensitivity to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitors across various tumor types. Howev...

Use of large language models to extract cancer diagnosis, histology, grade, and staging from unstructured electronic health records.

Gayathri Namasivayam, Zhaohui Su, Akhil Bhat et al. Jun 01, 2025 pp. 11176-11176 10.1200/jco.2025.43.16_suppl.11176

11176 Background: The oncology ecosystem contains millions of unstructured documents within Electronic Health Record (EHR) systems, including clinical not...

Trends and outcomes in Merkel cell carcinoma: A nationwide analysis of sociodemographic characteristics, inpatient utilization, and mortality (2016–2021).

Lina James George, Pierre Alexander Rodriguez Alarcon, Anil Mathew Philip et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21592

e21592 Background: Merkel cell carcinoma(MCC) is an aggressive, rapidly progressing neuroendocrine malignancy of the skin. We aimed to analyse the burden...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page